SCHEMBL25199491

SCHEMBL25199491

CC(C)(C)OC(=O)C1CCN(c2ccc(-c3ccc(OCc4ccccc4)nc3OCc3ccccc3)nc2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 5/20 0.43
CHRM4 P08173 3/20 0.39
GRM5 P41594 1/20 0.37
CYP4F2 P78329 1/20 0.37
CYP4A11 Q02928 1/20 0.37
TLR9 Q9NR96 1/20 0.36
F10 P00742 1/20 0.36
CKS1B P61024 1/20 0.36
SKP1 P63208 1/20 0.36
SKP2 Q13309 1/20 0.36
ENPP2 Q13822 1/20 0.36
CCNT1 O60563 1/20 0.35
CCNA2 P20248 1/20 0.35
CDK2 P24941 1/20 0.35
CDK9 P50750 1/20 0.35
CCNA1 P78396 1/20 0.35
CHRNB2 P17787 1/20 0.35
CHRNA7 P36544 1/20 0.35
CHRNA4 P43681 1/20 0.35
PRMT5 O14744 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25192135 0.89 GPR119 (0.39) GPR119GRM5F10ENPP2PRMT5
SCHEMBL25415347 0.86 PDK2 (0.40) GPR119GRM5TLR9F10ENPP2
SCHEMBL25439647 0.86 GPR119 (0.43) GPR119GRM5CKS1BSKP1SKP2
SCHEMBL30801284 0.86 GPR119 (0.59) GPR119TLR9CKS1BSKP1SKP2
SCHEMBL24671637 0.86 GPR119 (0.59) GPR119TLR9CKS1BSKP1SKP2
SCHEMBL25416238 0.86 PDK2 (0.39) GPR119CHRM4GRM5TLR9F10
SCHEMBL24671173 0.85 GPR119 (0.50) GPR119TLR9CCNT1CCNA2CDK2
SCHEMBL29991095 0.85 GPR119 (0.50) GPR119TLR9CCNT1CCNA2CDK2
SCHEMBL25200347 0.84 GPR119 (0.40) GPR119CHRM4GRM5TLR9CKS1B
SCHEMBL25074365 0.84 RET (0.40) GPR119CHRM4GRM5CKS1BSKP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400587-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF NURIX THERAPEUTICS INC (US) 2024-12-05 US disclosed
EP-4430052-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF Nurix Therapeutics, Inc. (US) 2024-09-18 EP disclosed
US-12091426-B2 Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof NURIX THERAPEUTICS, INC. (US) 2024-09-17 US disclosed
US-20240018162-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF NURIX THERAPEUTICS, INC. 2024-01-18 US disclosed
US-20240018162-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF NURIX THERAPEUTICS, INC. 2024-01-18 US disclosed
WO-2023086399-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF NURIX THERAPEUTICS, INC. (US) 2023-05-19 WO disclosed
WO-2023086399-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF NURIX THERAPEUTICS, INC. (US) 2023-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12091426-B2 Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof TTK, HIPK1, CLK1 GPR119 3689/4885CHRM4 4827/4885GRM5 4371/4885
US-20240400587-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF TTK, HIPK1, CLK1 GPR119 3689/4885CHRM4 4827/4885GRM5 4371/4885
US-20240018162-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF TTK, HIPK1, CLK1 GPR119 3689/4885CHRM4 4827/4885GRM5 4371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.